Human Microbiome Market Size Worth US$ 2,921.68 million by 2028 Lead By Seres Therapeutics; AOBiome; Kaleido Biosciences, Rebiotix

According to our new research study on "Human Microbiome Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Product, Disease, and Application," the market is expected to reach US$ 2,921.68 million by 2028 from US$ 718.95 million in 2021; it is estimated to grow at a CAGR of 22.2% during 2021-2028.

The human microbiome market, by disease, is segmented into diabetes, cancer, autoimmune disorders, obesity, mental disorders, and other diseases. Based on application, the market is segmented into diagnostics and therapeutics.

Get sample PDF Copy of human microbiome market @ https://www.theinsightpartners.com/sample/TIPBT00002233/?utm_source=OpenPR&utm_medium=10144

Based on product, the human microbiome market is further segmented into probiotics, foods, prebiotics, medical foods, diagnostic device, drugs and supplements. The human microbiome market on the basis of products is segmented into probiotics, foods, prebiotics, medical foods, diagnostic devices, drugs, and supplements. The probiotics segment is expected to hold the largest market share of 24.71% in 2021. This segment is also expected to dominate the market in 2028, and increasing concerns regarding health; growing awareness about the relation between nutrition, diet, and health; and surging penetration of probiotics in dairy and other food & beverages industries would favor the overall demand in the coming years. Furthermore, the prebiotics segment is anticipated to register the highest CAGR in the human microbiome market during 2021-2028.

Several microbiome projects have been launched worldwide with the aim to understand the roles played by these symbionts and their impact on the health of human host. The growth of the human microbiome market is attributed to the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies, and growing technological advancements in metagenomics and next-generation sequencing. However strict government guidelines and lack of knowledge about detailed examination hinders the market growth.

MaaT Pharma; ELIGO BIOSCIENCE; AOBiome; Kaleido Biosciences, Inc.; Seres Therapeutics; Merck & Co., Inc; Yakult Honsha Co., Ltd; Rebiotix, Inc.; DuPont de Nemours, Inc; and Synthetic Biologics, Inc. are among the leading companies operating in the human microbiome market.

As per World Health Organization, 13% of the world population (adults) was obese in 2016. According to the "The New Era of Treatment for Obesity and Metabolic Disorders: Evidence and Expectations for Gut Microbiome Transplantation," published in 2016, microbes residing in the human gastrointestinal tract act as an endocrine organ whose composition and functionality contribute to the development of obesity. Therefore, fecal/gut microbiome transplantation (GMT), involving the transfer of feces from a healthy donor to the patient, is a potential treatment for obesity.

Place an Order copy of this report @ https://www.theinsightpartners.com/buy/TIPBT00002233/?utm_source=OpenPR&utm_medium=10144

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876

This release was published on openPR.